MRP8/14 is an early and sensitive inflammation marker. It is released immediately in response to local inflammation. In contrast, other inflammatory markers are generated by downstream pathways and require de novo synthesis. Therefore, MRP8/14 is an ideal target for monitoring disease activity of Rheumatoid Arthritis. Our assays for MRP8/14 allow for precise and sensitive measurement of this important marker.
Circulating Immunecomplexes (CIC) are detectable in a variety of systemic disorders. They provide useful, clinical information regarding immunopathology, prognosis and follow-up of rheumatic and autoimmune disorders. Bühlmann Labs offers a well-established and widely used assay that provides sensitive results within 2 hours.
Measurement of anti-C1q autoantibodies in patients with Systemic Lupus Erythematosus (SLE) allows to determine the risk of developing an active lupus nephritis. Our anti-C1q autoantibody ELISA can be used as a simple way to exclude the risk of renal flair in the following months. In the case of active lupus nephritis, consecutive determination of anti-C1q antibodies is a tool to evaluate the efficacy of immunosuppressive treatment.